NAD+ and the NAD+ Salvage Pathway

What is NAD+?

Nicotinamide adenine dinucleotide (NAD+) is a coenzyme present in every living cell, serving as a critical electron carrier in cellular metabolism and a substrate for enzymes involved in DNA repair, epigenetic regulation, and cellular signaling. NAD+ exists in two forms: NAD+ (oxidized, electron acceptor) and NADH (reduced, electron carrier).

NAD+ is not merely a metabolic participant — it is a rate-limiting cofactor for multiple enzyme families that directly regulate aging and cellular health.

Core functions

Energy metabolism

NAD+ is essential for glycolysis, the tricarboxylic acid (TCA) cycle, and mitochondrial oxidative phosphorylation. It accepts electrons from metabolic intermediates (as NAD+ → NADH) and donates them to the electron transport chain for ATP production. Without NAD+, cellular energy production collapses.

DNA repair (PARP enzymes)

Poly-ADP-ribose polymerases (PARPs) consume NAD+ as a substrate to build poly-ADP-ribose chains at DNA damage sites, recruiting repair machinery. PARP1 alone can consume large quantities of NAD+ during genotoxic stress — creating competition between DNA repair and other NAD+-dependent processes.

Epigenetic regulation (sirtuins)

Sirtuins (SIRT1–7) are NAD+-dependent deacylases that regulate gene expression, mitochondrial biogenesis, inflammation, and stress resistance. SIRT1 (nuclear) and SIRT3 (mitochondrial) are the most extensively studied. Their activity is directly limited by NAD+ availability — when NAD+ declines, sirtuin activity declines proportionally.

Cellular signaling (CD38)

CD38 is an NAD+-consuming ectoenzyme whose expression increases with age and inflammation. It is increasingly recognized as a major driver of age-related NAD+ decline — CD38 expression increases ~2.5-fold in aged tissues, significantly increasing NAD+ consumption.

NAD+ decline with age

Tissue NAD+ levels decline approximately 50% between ages 40 and 60 in human studies. This decline is driven by:

• Increased consumption: PARP activation from accumulated DNA damage and CD38 upregulation from chronic inflammation both consume more NAD+
• Decreased synthesis: The NAD+ biosynthetic enzyme NAMPT (nicotinamide phosphoribosyltransferase) declines with age, reducing the efficiency of the salvage pathway
• NNMT diversion: Nicotinamide N-methyltransferase (NNMT) diverts NAD+ precursors by methylating nicotinamide to 1-methylnicotinamide, reducing the substrate available for NAD+ synthesis

The consequence is a cellular energy and signaling crisis — less ATP production, impaired DNA repair, reduced sirtuin activity, and compromised stress resistance.

The NAD+ salvage pathway

Most cellular NAD+ is recycled rather than synthesized de novo. The salvage pathway:

1. Nicotinamide (NAM, the product of sirtuin and PARP reactions) is converted to NMN (nicotinamide mononucleotide) by the enzyme NAMPT — the rate-limiting step
2. NMN is converted to NAD+ by NMN adenylyltransferases (NMNATs)

This cycle allows NAD+ to be continuously regenerated from its own breakdown products. Strategies to boost NAD+ target different points in this pathway:

• NMN supplementation: Bypasses the rate-limiting NAMPT step
• NR (nicotinamide riboside) supplementation: Enters the salvage pathway via nicotinamide riboside kinase (NRK)
• NNMT inhibition (5-Amino-1MQ): Prevents diversion of nicotinamide away from the salvage pathway
• CD38 inhibition: Reduces NAD+ consumption by blocking the major consumer

Peptide connections to NAD+ biology

MOTS-c

The mitochondrial-derived peptide MOTS-c activates AMPK, which in turn upregulates NAMPT expression and mitochondrial NAD+ production. MOTS-c effectively enhances the NAD+ salvage pathway from the demand side — improving the efficiency of NAD+ utilization in mitochondrial energy production.

5-Amino-1MQ

This NNMT inhibitor blocks the enzyme that diverts nicotinamide away from the NAD+ salvage pathway. By inhibiting NNMT, 5-Amino-1MQ increases the substrate available for NAMPT → NMN → NAD+ conversion. In adipose tissue (where NNMT is overexpressed in obesity), this restores NAD+ levels and shifts adipocyte metabolism toward oxidation.

SS-31 (Elamipretide)

SS-31 stabilizes cardiolipin on the inner mitochondrial membrane, restoring electron transport chain efficiency. This reduces NADH accumulation at the ETC and improves the NAD+/NADH ratio — functionally increasing available NAD+ without increasing total NAD+ production.

Clinical relevance

NAD+ decline is increasingly recognized as a druggable node in the aging process. Human trials of NMN and NR supplementation have shown improved insulin sensitivity, vascular function, and exercise capacity in some but not all studies. The combination of NAD+ precursor supplementation with peptide-based approaches (MOTS-c, 5-Amino-1MQ) represents a multi-target strategy for NAD+ restoration — though clinical evidence for the combination approach is absent.

The key principle: NAD+ is a rate-limiting resource that multiple age-related processes compete for. Restoring NAD+ levels may not fix any single disease, but may improve the cellular operating environment broadly.